



MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

- Investor Webcast to Discuss Phase 3 LEVADEX(TM) Data Presented in Late-Breaking Session at the 14th Congress of the International Headache Society -

MOUNTAIN VIEW, Calif., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will participate in the following events in September:

Thomas Weisel Partners Healthcare Conference 2009
Friday, September 11, at 10:20 a.m. ET in Boston

14th Congress of the International Headache Society
September 10 to 13, in Philadelphia
Late-Breaking oral platform presentation on Saturday, September 12, at
7:35 a.m. ET
Three posters can be viewed during the conference

Webcast to discuss Phase 3 LEVADEX(TM) data presented in a late-breaking
session at the 14th Congress of the International Headache Society
Monday, September 14th at 7:15 a.m. ET

Morgan Stanley Global Healthcare Conference
Monday, September 14, at 1:00 p.m. ET in New York City

Live webcasts of the events on Friday, September 11 and Monday, September 14 will be available in the Investor Relations section of MAP Pharmaceuticals' website at <http://www.mappharma.com>. A replay will also be available within 24 hours for at least seven days following each presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

CONTACT:

Lisa Borland
(650) 386-3122

<http://www.mappharma.com>

SOURCE MAP Pharmaceuticals, Inc.

<http://www.mappharma.com>

Copyright (C) 2009 PR Newswire. All rights reserved